Navigation Links
Zevacor Molecular to Open Only Commercial 70 MeV Cyclotron Dedicated to Medical Use in the United States
Date:9/25/2013

INDIANAPOLIS, Sept. 25, 2013 /PRNewswire/ -- The Zevacor Molecular Board of Directors announced approval of funding to purchase the only 70 MeV commercial cyclotron dedicated to medical use in the United States. Zevacor Molecular is engaged with various vendors and will award the contract within 30 days. The 70 MeV cyclotron, expected to be operational in the fall of 2016, will expand Zevacor Molecular's pharmaceutical line.

Zevacor Molecular, an independently owned healthcare firm that manufactures and distributes PET and SPECT radiopharmaceuticals, has committed to this multi-million dollar project to introduce a commercial medical 70 MeV Cyclotron in order to stabilize the domestic supply of medical isotopes needed to diagnose and treat critical illnesses.

"Medical isotopes are critical to early and accurate diagnosis of cancer, heart disease and a number of other life threatening diseases," said Zevacor Molecular Executive Vice President and Chief Operating Officer John Zehner. "In the past, the supply of medical isotopes has not been continuous, making it difficult to offer these diagnostics and therapeutics. This investment will allow us to provide year round production of medically necessary isotopes for patients."

Zevacor Molecular was established in 2012. Zevacor's efforts come at a time when there is little certainty of supply in the market for medical isotopes. The 70 MeV will have the ability to supply patients with medically necessary isotopes used for diagnostic imaging and therapies within oncology, neurology and cardiology. Although the project is focused on Strontium (Sr-82), which is the raw material for Rubidium (Rb-82) generators, it also opens up several research isotopes currently not widely available in the United States such as Copper-67 which is a therapeutic for treating cancer.


'/>"/>
SOURCE Zevacor Molecular
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. QIAGEN and Cardinal Health Collaborate to Offer Molecular Diagnostic Products to Smaller and Mid-sized U.S. Hospitals
2. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
3. Frost & Sullivan: Expanding Sample Prep Market Supports Growth Trends in Molecular Diagnostics Markets
4. QIAGEN Unveils Initiative to Create Next-Generation Sequencing Portfolio for use in Clinical Research and Molecular Diagnostics
5. The 2012 US Molecular Diagnostics Market
6. BSGI Molecular Breast Imaging Provides Better Results than MRI for Cancer Patients with Dense Breasts
7. BSGI Molecular Breast Imaging Proves Equivalent to MRI in Breast Cancer Patient Management
8. Amsterdam Molecular Therapeutics (AMT) Holding N.V. (in liquidation) Announces Publication of its Accounts for 2011 and Notice of Annual General Meeting
9. Science Translational Medicine and the DMM Global Foundation Announce Days of Molecular Medicine 2012 "The Translational Science of Rare Diseases: From Rare To Care."
10. IBA Molecular, Piramal Imaging Sign Agreement for New F-18 Amyloid Imaging Agent
11. New Molecular Assay Allows Healthcare Facilities to Simplify Active Surveillance Testing for Deadly Superbug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017  Vivify Health, the pioneer ... has been awarded a very significant patent for the ... to continual care via digital health.  This landmark patent ... property and further secures Vivify,s position as the leader ... 2009, was the first company to apply consumer mobile ...
(Date:4/20/2017)... 2017  CVS Pharmacy, the retail division of ... store design to enhance the retail customer experience ... products and expanded beauty selections paired with informational ... new offerings. Together with its innovative digital programs, ... customer experience at CVS Pharmacy.  ...
(Date:4/20/2017)... 20, 2017 NeuroVive Pharmaceutical AB (Nasdaq ... positive preclinical results demonstrating anti-fibrotic effects with ... steatohepatitis (NASH), in an additional well-validated experimental ... has previously shown similar anti-fibrotic effects in ... scientists present novel data demonstrating anti-fibrotic effects ...
Breaking Medicine Technology:
(Date:4/22/2017)... ... April 22, 2017 , ... ... Security of Philadelphia its “Woman-Owned Small Business of the Year, eastern ... information destruction , recycling, and compliance services to businesses throughout eastern ...
(Date:4/22/2017)... ... April 22, 2017 , ... Brian Emmer brings more ... Sales and Business Development at OAKWORKS, Inc. Mr. Emmer is responsible for ... strategic planning for the company. Recognized industry-wide as a healthcare innovator, Emmer ...
(Date:4/21/2017)... ... ... An April 10 article in the Daily Mail describes the ... deal about prehistoric ice-age dental practitioners and their primitive and, no doubt, painful techniques. ... dental matter, and that teeth were then filled with bitumen, a substance similar to ...
(Date:4/21/2017)... ... ... staff at Palm Beach Face is proud to announce that their practice founder, Michael ... take place on April 23rd, the London Marathon has a long tradition of raising funds ... team EMPOWER, raising money for the international charity, Smile Train. , Started in ...
(Date:4/21/2017)... ... April 21, 2017 , ... Chicago plastic surgeon, Dr. Anil R. ... osteoma is a benign bony lump located on the forehead usually attributed to a ... with sight and pain. Dr. Shah has discovered an approach that is minimally invasive. ...
Breaking Medicine News(10 mins):